Medication info
Olmesartan Medoxomil 20/10 Milligrams

Olmesartan Medoxomil 20/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
White or light-yellow round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]
Approval status
Active

MFDS item code 202003957 · Approved 2020.05.28

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Elderly patients No dose adjustment is necessary when administering this medicine to elderly patients aged 65 years or older. Although no overall differences in the efficacy and safety of this medicine have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20mg once daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients requiring simultaneous administration of olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil helps treat essential hypertension. Rosuvastatin improves hypercholesterolemia and mixed dyslipidemia that are not controlled by diet and exercise, and it is also used as an adjunctive therapy for homozymous familial hypercholesterolemia. Additionally, it helps lower cholesterol levels in patients with hypercholesterolemia, delays the progression of atherosclerosis, and serves as an adjunctive therapy for diet in cases of abnormal beta-lipoproteinemia. For high-risk patients with cardiovascular disease, it aids in reducing the risks of stroke, myocardial infarction, and vascular reconstruction. Thus, this medication is effectively used for the treatment of hypertension and various lipid abnormalities as well as for reducing cardiovascular risks.

How to take

Adult dose

This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Elderly patients No dose adjustment is necessary when administering this medicine to elderly patients aged 65 years or older. Although no overall differences in the efficacy and safety of this medicine have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20mg once daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn, especially if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be taken by individuals allergic to this medication or its components, pregnant women, women of childbearing potential, nursing mothers, or patients with severely impaired kidney or liver function. Patients with very low blood pressure or decreased blood volume, severe heart failure, and those with impaired kidney function should use this medication with special caution and may require close monitoring when treatment begins. This medication may cause myalgia, myopathy, and rarely serious muscle damage (rhabdomyolysis), so any unusual muscle symptoms should be reported to medical staff immediately. Liver function abnormalities may occur, so it is important to undergo regular liver function tests before and during treatment. Since this medication lowers blood pressure, dizziness or drowsiness may occur, caution should be exercised when driving or operating dangerous machinery. Drug interactions may occur when taken with other medications, so it is important to inform your doctor or pharmacist of any other medications you are taking. This medication contains lactose, so individuals with lactose intolerance should avoid it. Pregnant or nursing women should avoid taking this medication, and women of childbearing potential should employ appropriate contraceptive methods. Elderly patients or those with impaired kidney function may require dosage adjustments, so they should follow their healthcare provider's instructions. Overdosage may cause symptoms such as low blood pressure and palpitations, so you should seek medical attention immediately if these symptoms occur. To ensure child safety, this medication should be stored out of the reach of children, and transferring it to another container should be avoided.

Side effects

Elevation of ALT, elevation of AST, increase in blood creatinine, decreased creatinine clearance, headache, dizziness, perceptual decline, neuromuscular disease, drowsiness, gastroesophageal reflux, constipation, tooth decay, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest pain, peripheral edema, dizziness, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, angioedema, anaphylaxis, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, itching, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), palpitations, increased blood pressure, low back pain, increased serum creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia gravis, ocular myasthenia gravis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering and should be kept at a temperature between 1°C and 30°C. This will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

White or light-yellow round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.